Korro Bio Inc Reports Q3 2026 Loss of $0.98 Per Share, Revenue Misses Estimates at $0 Million
RNA-editing biotech narrows its quarterly loss and holds $124.8 million in cash, extending its runway into the second half of 2028 Related Stocks: KRRO ,
RNA-editing biotech narrows its quarterly loss and holds $124.8 million in cash, extending its runway into the second half of 2028 Related Stocks: KRRO ,